RU2016139697A - Комбинация, содержащая ингибитор btk и ингибитор akt - Google Patents
Комбинация, содержащая ингибитор btk и ингибитор akt Download PDFInfo
- Publication number
- RU2016139697A RU2016139697A RU2016139697A RU2016139697A RU2016139697A RU 2016139697 A RU2016139697 A RU 2016139697A RU 2016139697 A RU2016139697 A RU 2016139697A RU 2016139697 A RU2016139697 A RU 2016139697A RU 2016139697 A RU2016139697 A RU 2016139697A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- combination
- amino
- chloro
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461951640P | 2014-03-12 | 2014-03-12 | |
| US61/951,640 | 2014-03-12 | ||
| PCT/IB2015/051380 WO2015136398A1 (en) | 2014-03-12 | 2015-02-24 | Combination comprising a btk inhibitor and an akt inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016139697A true RU2016139697A (ru) | 2018-04-12 |
| RU2016139697A3 RU2016139697A3 (cg-RX-API-DMAC7.html) | 2018-10-19 |
Family
ID=52630445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016139697A RU2016139697A (ru) | 2014-03-12 | 2015-02-24 | Комбинация, содержащая ингибитор btk и ингибитор akt |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170020878A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3116546A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017507963A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160127754A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106456642A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015228475B9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2942204A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016011674A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016139697A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015136398A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| NZ594064A (en) * | 2009-01-30 | 2012-08-31 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| ES2590491T3 (es) | 2011-05-17 | 2016-11-22 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
| WO2013010869A1 (en) | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| JP2014532658A (ja) | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
| CA2852964A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Bicyclic piperazine compounds |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| CN104169260A (zh) | 2012-03-09 | 2014-11-26 | 卡尔那生物科学株式会社 | 新三嗪衍生物 |
| WO2013161848A1 (ja) | 2012-04-27 | 2013-10-31 | カルナバイオサイエンス株式会社 | 新規1,2,4-トリアジン誘導体 |
| MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
-
2015
- 2015-02-24 CN CN201580013442.2A patent/CN106456642A/zh active Pending
- 2015-02-24 CA CA2942204A patent/CA2942204A1/en not_active Abandoned
- 2015-02-24 EP EP15708605.9A patent/EP3116546A1/en not_active Withdrawn
- 2015-02-24 WO PCT/IB2015/051380 patent/WO2015136398A1/en not_active Ceased
- 2015-02-24 MX MX2016011674A patent/MX2016011674A/es unknown
- 2015-02-24 JP JP2016556821A patent/JP2017507963A/ja active Pending
- 2015-02-24 US US15/124,301 patent/US20170020878A1/en not_active Abandoned
- 2015-02-24 AU AU2015228475A patent/AU2015228475B9/en not_active Ceased
- 2015-02-24 KR KR1020167024720A patent/KR20160127754A/ko not_active Withdrawn
- 2015-02-24 RU RU2016139697A patent/RU2016139697A/ru not_active Application Discontinuation
-
2018
- 2018-06-18 US US16/010,945 patent/US20190151319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170020878A1 (en) | 2017-01-26 |
| CN106456642A (zh) | 2017-02-22 |
| KR20160127754A (ko) | 2016-11-04 |
| WO2015136398A1 (en) | 2015-09-17 |
| JP2017507963A (ja) | 2017-03-23 |
| AU2015228475B2 (en) | 2017-08-17 |
| AU2015228475A1 (en) | 2016-09-01 |
| US20190151319A1 (en) | 2019-05-23 |
| RU2016139697A3 (cg-RX-API-DMAC7.html) | 2018-10-19 |
| AU2015228475B9 (en) | 2017-09-21 |
| CA2942204A1 (en) | 2015-09-17 |
| EP3116546A1 (en) | 2017-01-18 |
| MX2016011674A (es) | 2017-04-27 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190212 |